Integra LifeSciences Holdings Corporation — FY2014 Form 10-K Summary
Business context and reporting period
Integra is a global medical technology company providing regenerative technologies, neurosurgical products, extremity reconstruction, orthopedic and tissue technologies, surgical instruments, and spine hardware and orthobiologics. The filing covers the fiscal year ended December 31, 2014; fourth-quarter revenue was $252.2 million and fourth-quarter net income was $17.2 million.
The company operated through five reportable segments: U.S. Neurosurgery, U.S. Instruments, U.S. Extremities, U.S. Spine and Other, and International. Integra employed approximately 3,400 people and generated 77% of revenue from the United States.
Financial performance and position
| Metric | 2014 | 2013 | Change |
|---|---|---|---|
| Revenue | $928.3 million | $836.2 million | +11% |
| Gross profit | $575.5 million | $509.2 million | +13% |
| Gross margin | 62.0% | 60.9% | +110 bps |
| Operating income | $65.5 million | $(10.2) million | Improved |
| Net income | $34.0 million | $(21.1) million | Improved |
| Diluted EPS | $1.03 | $(0.74) | Improved |
| Operating cash flow | $79.5 million | $53.3 million | +49% |
| Capital expenditures | $41.9 million | $47.9 million | Lower |
- Revenue growth was led by Neurosurgery, which increased 42% to $371.7 million at the product-category level, including $54.1 million of incremental DuraSeal revenue from the Confluent Surgical acquisition.
- Orthopedics revenue was $370.1 million, approximately flat year over year, while Instruments revenue declined slightly to $186.5 million.
- U.S. Neurosurgery segment revenue increased to $244.6 million; U.S. Extremities increased to $143.4 million; International increased to $211.1 million. U.S. Instruments declined to $157.8 million and U.S. Spine and Other declined to $171.4 million.
- Total operating expenses declined 2% to $510.0 million, although selling, general and administrative expense increased 9.4% to $446.0 million due to acquisitions, sales-force expansion, ERP depreciation, strategic consulting, severance, and spin-off costs.
- Interest expense increased to $22.0 million from $19.8 million, primarily due to higher borrowings and reduced capitalization of ERP-related interest.
- Cash and cash equivalents were $72.0 million at year-end, compared with $120.6 million at December 31, 2013. Working capital was $403.3 million.
- Net cash used in investing activities was $363.3 million, including $320.9 million for acquisitions and $41.9 million for capital expenditures. Financing activities provided $242.8 million.
- Total assets increased to $1.58 billion, including $363.9 million of goodwill and $459.5 million of net intangible assets. Stockholders’ equity was $704.3 million.
Material changes versus the prior comparable period
- Integra returned to profitability, compared with a 2013 net loss that included a $46.7 million non-cash goodwill impairment charge related to U.S. Spine.
- Gross margin improved primarily from higher-margin DuraSeal sales, lower inventory reserves and scrappage following the 2013 collagen-product recall, and lower manufacturing remediation costs.
- 2014 acquisitions included Confluent Surgical for approximately $255.9 million, MicroFrance for approximately $61.6 million, and Metasurg for approximately $27.2 million.
- The company changed its accounting for the medical device excise tax retrospectively. The tax is now recorded in selling, general and administrative expense when the first U.S. sale occurs rather than in inventory and cost of goods sold.
- Integra closed and delisted its Andover, United Kingdom facility on December 31, 2014. The Añasco, Puerto Rico FDA warning letter was subsequently closed on January 14, 2015; the Plainsboro warning letter had been closed in 2013.
- The company implemented its ERP system across approximately 80% of revenue and continued facility consolidation, manufacturing transfers, product rationalization, and organizational restructuring.
- In November 2014, Integra announced plans to spin off its spine business into a separate public company, expected before September 2015, subject to customary conditions.
Guidance, outlook, risks and unusual items
- Management expected 2015 gross margin of 61.5% to 62.0%, research and development expense of approximately 6.0% of revenue, reported SG&A of 47% to 48% of revenue, and a worldwide effective tax rate of approximately 24% to 25%.
- Planned 2015 cash uses included $40 million to $45 million of capital expenditures, $30 million to $40 million of cash to the spine business in connection with the spin-off, and approximately $20 million of professional fees and other separation costs.
- Management anticipated approximately $25 million of unfavorable 2015 revenue impact from foreign currency movements, based on then-current exchange rates.
- The company expected to commercialize a diabetic foot-ulcer product in mid-2016, assuming FDA approval and timely publication of clinical data. The PMA supplement was filed in February 2015.
- 2014 special charges totaled $68.5 million, including $23.2 million of ERP implementation costs, $13.7 million of structural optimization costs, $9.4 million of acquisition-related costs, $9.1 million of employee termination costs, $2.2 million of SeaSpine spin-off costs, and $7.1 million of non-cash convertible-debt interest.
- Debt consisted principally of $416.9 million outstanding under the senior credit facility and $230.0 million principal amount of 1.625% convertible notes due December 2016. The credit facility provided approximately $483.1 million of additional borrowing capacity at year-end and matured in 2019 after the 2014 refinancing.
- Key risks include execution and cost overruns associated with the spine spin-off and ERP implementation, acquisition integration, reimbursement and pricing pressure, FDA and foreign regulatory compliance, product recalls and liability, reliance on certain suppliers and tissue banks, foreign-exchange exposure, competition, goodwill and intangible-asset impairment, and refinancing the 2016 convertible notes.
- The company reported no material off-balance-sheet arrangements and stated that it was in compliance with its credit-facility covenants at December 31, 2014.
Most important facts for investors to verify
- Completion, timing, funding arrangements, tax treatment, and ongoing costs of the SeaSpine spin-off.
- Integration performance and cash returns from the Confluent Surgical, MicroFrance, and Metasurg acquisitions.
- Progress and cost savings from facility consolidation and ERP implementation.
- FDA compliance and the absence of new warning letters, recalls, or manufacturing disruptions.
- Ability to refinance or repay the $230.0 million convertible notes due in 2016 and manage variable-rate debt.
- Impact of foreign-exchange movements, reimbursement changes, medical device taxes, and pricing pressure on 2015 revenue and margins.
- Regulatory approval, reimbursement, and commercialization timing for the diabetic foot-ulcer product.
- Potential impairment of goodwill and intangible assets, particularly amid weakness in spine and instruments markets.